City Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
City Therapeutics Inc. - overview
Established
2018
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded by co-founders Sebastian Trousil Ph. D. and John Maraganore Ph. D.
, City Therapeutics Inc. operates as a provider of engineered small interfering RNAs (siRNAs) to biotechnology firms and healthcare organizations for developing innovative RNAi therapies. In October 2024, City Therapeutics Inc. raised USD 135 million in Series A funding led by ARCH Venture Partners, with participation from Fidelity Investments, Invus, Slate Path Capital Lp, Rock Springs Capital, Regeneron Ventures, and AN Ventures.
The company provides a wide range of biotechnology solutions, such as small interfering RNAs (siRNAs), engineered RNAi trigger molecules, targeting ligands for enhanced cellular uptake, and advanced therapeutic targets. Additionally, the firm also provides services such as clinical development optimization for RNAi-based medicines and support for therapeutic target identification. The company plans to use its proceeds from October 2024 funding to advance innovations in siRNA design and delivery to improve potency, specificity, and access across various tissue types for multiple therapeutic applications.
Current Investors
ARCH Venture Partners, Invus [DUP], Fidelity Investments
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.citytx.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.